PTO/SB/26 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ÉRMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT

Docket Number (Optional)
WORLD-01004US3

u/2/06

In re Application of: Terwilliger and Lamoureux

Application No.: 10/716,333 Filed: November 18, 2003

<sub>For</sub> DELIVERY FOR INTERSTITIAL RADIOTHERAPY USING HOLLOW SEEDS

The owner\*, WORLDWIDE MEDICAL TECHNOLOGIES LLC, of part interest in the instant application, and collectively with IDEAMATRIX, INC of 100% interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 7,008,368 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantees, their successors or assigns.

In making the above disclaimer, the owners do not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the **prior patent**, "as the term of said **prior patent** is presently shortened by any terminal disclaimer," in the event that said **prior patent** later:

expires for failure to pay a maintenance fee;

is held unenforceable,

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissued; or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. 🔽	For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency
	etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2.		The undersigned is an attorney or agent of record.	Reg. No.	
----	--	--	----------	--

Gary Lamoureux
WORLDWIDE MEDICAL TECHNOLOGIES LLC

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: WORLD-01004US3

PTO/SB/26 (07-06)

Approved for use through 09/30/2005 OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## MINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING **REJECTION OVER A "PRIOR" PATENT**

Docket Number (Optional) WORLD-01004US3

In re Application of: Terwilliger and Lamoureux

Application No : 10/716,333 Filed November 18, 2003

DELIVERY FOR INTERSTITIAL RADIOTHERAPY USING HOLLOW SEEDS

The owner", IDEAMATRIX, INC, of part interest in the instant application, and collectively with WORLDWIDE MEDICAL TECHNOLOGIES LLC of 100% interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent No. 7,008,368 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is hinding upon the grantees, their successors or assigns.

In making the above disclaimer, the owners do not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, 'as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

expires for failure to pay a maintenance fee;

is held unenforceable:

is found invalid by a court of competent jurisdiction;

is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;

has all claims canceled by a reexamination certificate;

is reissued; or

is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any potent issued thereon.

The undersigned is an attorney or agent of record.

Richard A. Terwilliger IDEAMATIRX, INC

Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement\_under 37 CFR 3,73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gariteting, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be certified the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SCND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.; WORLD-01004US3

PTO/SB/96 (12-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of into	
STATEMENT UNDER 37 CFR 3.73(b	
Applicant/Patent Owner: WORLDWIDE MEDICAL TECHNOLOGIES	LLC (part interest)
Application No./Patent No./Control No.: 10/716,333 Filed/Issue Date:	November 18, 2003
Entitled: DELIVERY FOR INTERSTITAL RADIOTHERAPY USING HOLLOW	W SEEDS
WORLDWIDE MEDICAL TECHNOLOGIES LLC (part interest) , a Corporation	
(Name of Assignee) (Type of Assignee: corport states that it is:  1 the assignee of the entire right, title, and interest; or	ation, partnership, university, government agency, etc.
2. 🗾 an assignee of part interest	
in the patent application/patent identified above by virtue of either:	
<ul> <li>A. An assignment from the inventor(s) of the patent application/patent identified a in the United States Patent and Trademark Office at Reel 017073 , Francoriginal assignment is attached.</li> <li>OR</li> <li>B. A chain of title from the inventor(s), of the patent application/patent identified a</li> </ul>	ne <u>0913</u> , or a true copy of the
1. From:	
1. From: To: To: The document was recorded in the United States Patent and Trademar Reel, or for which a copy	k Office at thereof is attached.
From: To: To: The document was recorded in the United States Patent and Trademar	
The document was recorded in the United States Patent and Trademar Reel, Frame, or for which a cop	k Office at by thereof is attached.
3. From: To:	
The document was recorded in the United States Patent and Trademar Reel, or for which a co	
Additional documents in the chain of title are listed on a supplemental shee	ıt.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of the assignee was, or concurrently is being, submitted for recordation pursuant to [NOTE: A separate copy (i.e., a true copy of the original assignment document(solve). Division in accordance with 37 CFR Part 3, to record the assignment in the 302.08]	37 CFR 3.11.  i)) must be submitted to Assignment
The undersigned (whose title is supplied below) is authorized to act on behalf of the	assignee. 11/2/06
Signature	Date 203-262 - 419 4
Gary Lamoureux	
Printed or Typed Name	Telephone Number
President and CEO  Title	
ride	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: WORLD-01004US3

NOV 2 1 2006 L

PTO/SB/96 (12-05)
Approved for use through 07/31/2000, OMB 0691-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OME control number.

STATEMENT UNDER 37 CFR 3.73(B)				
Applicant/Patent Owner: IDEAMATRIX, INC. (part interest)				
Application No./Patent No./Control No.: 10/716,333 Filed/Issue Date: November 18, 2003				
Entitled: DELIVERY FOR INTERSTITIAL RADIOTHERAPY USING HOLLOW SEEDS				
IDEAMATRIX, INC. (part interest)				
(Name of Assignee) (Type of Assignee, corporation, partnership, university, government agency, etc.) states that it is:  1. [ ] the assignee of the entire right, title, and interest; or				
2. 🕢 an assignee of part interest				
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014227, Frame 0296, or a true copy of the original assignment is attached.  OR  B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
L1				
To:  The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
2 From:To:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
3 From: To:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.  [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature Signature 310 401 0260				
Printed or Typed Name Telephone Number				
President				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerco, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: WORLD-01004US3